This article was originally published in The Tan Sheet
Recommendations by FDA's Nonprescription Drugs Advisory Committee meeting June 12 to discontinue Ipecac's OTC status "do not adequately represent the perspective of many practicing medical toxicologists," Richard Dart, MD/PhD, says in July 22 comments filed with the agency (1"The Tan Sheet" June 16, 2003, p. 3). Ipecac is useful in cases of iron and acetaminophen ingestion and for households in rural areas, the Rocky Mountain Poison Center Director argues. Therefore, Dart requests FDA wait until the tentative final monograph for OTC Poison Treatment Drug Products is "adopted before making its decision on the fate of syrup of Ipecac"...
You may also be interested in...
Ipecac syrup should not retain its OTC status as a treatment for accidental poisonings, a majority of the FDA Nonprescription Drugs Advisory Committee agreed at a June 12 meeting in Bethesda, Md
Increasing clinical trial complexity goes hand in hand with increased reliance on advanced-analysis software. Raj Indupuri of eClinical Solutions believes the company's product will lead this emerging market.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.